A research group at Faculty of Medicine "Vaccine to reduce the size of myocardial infarction and prevent heart failure" was successfully developed.

A research team led by Professors Koichi Node and Aya Shiraki of the Department of Cardiology at Saga University Faculty of Medicine has successfully developed a vaccine that reduces the size of myocardial infarction and prevents heart failure. The effectiveness of the vaccine was confirmed in experiments with mice and the team will now proceed to study its application in humans. The research paper was published in the British scientific journal Scientific Reports.

Currently, the effectiveness of the vaccine has been evaluated only in rats, so development of a humanized vaccine has been initiated. In addition, because it takes time to produce antibodies if the vaccine is administered after the onset of myocardial infarction, we are working with the International University of Health and Welfare to develop monochromatic antibodies capable of immediate treatment. We are also investigating the application of other disease models, such as a lower extremity ischemia model, a heart failure model, a hypertension model, and a stroke model.
If the development of the vaccine becomes practical, it may be useful for prevention, treatment and prevention of recurrence.

Scientific Reports published online (2022/4/28)。A Novel Soluble Epoxide Hydrolase Vaccine Protects Murine Cardiac Muscle Against Myocardial Infarction. Scientific Reports (2022)12:6923.